Navigation Links
Proceedings of the National Academy of Sciences Report Superiority of Human Growth Hormone Generated with Ambrx Technology
Date:5/25/2011

SAN DIEGO, May 25, 2011 /PRNewswire/ -- Ambrx Inc. today announced that data from a Phase 1/2 study, published online ahead of print on May 16 by Proceedings of the National Academy of Sciences, demonstrate the safety, efficacy and superior dosing frequency of ARX201, a sustained action human growth hormone, compared to therapy with native hormone.

The study evaluated adult GH-deficient (AGHD) patients treated with ARX201, which was generated with Ambrx's ReCODE™ technology. ARX201 was shown to have a half-life in patients of four days and to potentially be suitable for weekly dosing, which is superior to current therapy that requires daily dosing. Insulin-like growth factor 1 (IGF-1) a clinically validated biomarker of growth hormone activity was restored to normal ranges with weekly dosing.  ARX201 was found to be safe and well tolerated with repeat dosing.

"This report provides clinical validation of Ambrx technology, which constitutes site-directed protein medicinal chemistry," said Ho Cho, Ph.D., Chief Technology Officer of Ambrx. "ARX201 represents a best in class growth hormone optimized for efficacy, safety and patient convenience. Additionally, Ambrx has successfully scaled the manufacturing process to support advanced product development and eventual commercialization."

The study enrolled 22 AGHD patients who had not received growth hormone replacement therapy in the past six months.  Patients received weekly injections of ARX201 for up to 26 weeks.  ARX201 dose was determined through measurement of IGF-1, the standard indicator for growth hormone therapy.  Efficacy in patients included decreased truncal fat mass and total body fat, while lean body mass levels increased.

About ARX201

ARX201 is a long-acting rDNA-derived human GH drug candidate being developed by Ambrx for the treatment of growth hormone deficiencies. A Phase 2b clinical trial of ARX201 in adult patients with gr
'/>"/>

SOURCE Ambrx Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
2. Data Published in Proceedings of National Academy of Sciences Highlights Potential of Micromets BiTE Antibody Platform
3. London Genetics Conference Proceedings Published in Drug Discovery Today
4. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
5. Mayo Clinic Proceedings: A Comprehensive Review of Addiction to Prescription Painkillers Among Patients and Physicians
6. Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases
7. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
9. Mayo Clinic Proceedings Contributors Highlight Research Findings About Cardiovascular Benefits Associated With Omega-3 Fatty Acids
10. Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System
11. Mayo Clinic Proceedings January Tip Sheet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- Integrated Silicon Solution, Inc. (Nasdaq: ISSI ... solutions, today announced that it will host its earnings ... a.m. Pacific Time (10:00 a.m. Eastern Time) to discuss ... quarter ended June 30, 2014. To access ... a.m. Pacific time on July 24, 2014.  The participant ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
(Date:1/15/2014)... 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced ... 2013, compared to sales of $2,202,000 for the prior year ... quarter has also shown growth over the preceding quarter,s sales, ... this fiscal year. Markets that experienced sales increases over the ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... CITY, Feb. 28, 2011 Concentra, a subsidiary of ... the future of occupational and urgent care through a ... experiences for clients and patients. Recent customer loyalty ratings ... of top U.S. consumer companies as a leader in ...
... ISLAND, N.Y., Feb. 28, 2011  A 67-year-old man with ... wife after wandering outside in near-freezing temperatures thanks to the ... watch-like EmSeeQ® wearable locator device. Robert ... discovered him missing. He was located on Victory Boulevard, more ...
Cached Medicine Technology:Concentra is Writing a New Prescription on Health Care With Outstanding Service 2Concentra is Writing a New Prescription on Health Care With Outstanding Service 3Concentra is Writing a New Prescription on Health Care With Outstanding Service 4Concentra is Writing a New Prescription on Health Care With Outstanding Service 5Staten Island Man Now Safe at Home Thanks to EmSeeQ® Locator Device 2Staten Island Man Now Safe at Home Thanks to EmSeeQ® Locator Device 3
(Date:7/10/2014)... widespread across the United States, due in large to ... of clinical data that will become available for research ... experts in healthcare have become increasingly focused on clinical ... purpose of gleaning insights that have the potential to ... that is known as big data. ...
(Date:7/10/2014)... Adults with dyslexia are more likely to report that ... people who don,t have the learning disorder, according to ... to 10 percent of people, causes problems with reading ... with this condition said they suffered physical abuse during ... dyslexia. "Even after accounting for age, race, sex ...
(Date:7/10/2014)... News) -- Men who have a vasectomy may be ... study suggests. But the risk is comparatively small, ... the study said more research is needed to determine ... the study, Harvard researchers analyzed data from more than ... starting in 1986. During that time, 6,023 cases of ...
(Date:7/10/2014)... 2014In response to today,s announcement that the "Mississippi Baby," ... now been found to have detectable levels of the ... disappointment in this setback but remains hopeful that the ... remain undetectable for more than two years will continue ... ultimately develop a cure. , "Although we had ...
(Date:7/10/2014)... device developed at the Massachusetts General Hospital (MGH) Center ... can be cultured to establish cell lines for genetic ... issue of Science , an MGH research team ... genetic mutation over time and changing susceptibility to therapeutic ... the blood that represent those present in metastatic deposits, ...
Breaking Medicine News(10 mins):Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 3
... BALTIMORE, April 30 MDDCcommunity.com would like to announce ... local member company. Over the past few months Dynasplint(R) ... establishing more of a presence online. Their expansion includes ... Twitter account, all of which are intended to provide ...
... April 30 The Missouri House today amended ... funds to go to grants for maternity homes and pregnancy ... being considered by the Missouri Senate. , , ... homes and pregnancy resource centers are essential to helping pregnant ...
... The ,Help is Here Express, bus tour will be stopping ... 8th at various cities in order to help uninsured and ... for free or nearly free. With the state,s unemployment rate ... is ready to help state residents who face layoffs and ...
... YORK and NASSAU, The Bahamas, April 30 ... of Fincor (FINC) through a 1:1 share split. Prospero ... Technologies enlarges thru Fincor its portfolio with the new ... the WETTECH and Advanced Cavitation Technologies. Prospero ...
... are abandoned again! WEST PALM BEACH, Fla., April ... a civil rights and negligence lawsuit in New York ... Welfare Administration and four other agencies for failure to ... state-licensed foster parent.Identified in the filing only by their ...
... and psychological repercussions that impact quality of life and ... ability to remain employed. Compared to individuals with other ... have a more profound effect on a person,s ability ... of those with severe forms of arthritis were not ...
Cached Medicine News:Health News:Dynasplint Systems, Inc. Launches Two New Web Sites Plus Social Media Tools 2Health News:Partnership for Prescription Assistance Prepared to Help Kansan Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Kansan Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Kansan Workers Hurt by Recession 4Health News:Prospero Group (PRPG) and Fincor (FINC) Made a Share Transfer and Enter the Market with ACTRx a New Malaria and Dengue Fever Treatment 2Health News:Severely Abused Foster Children Sue New York City Child Welfare Agencies After their Failure to Help Them 2Health News:Women with arthritis more likely than men to stop working 2Health News:Women with arthritis more likely than men to stop working 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: